- Home
- Study Options
- Research
- Business Services
- Our Staff
- About Us
- Contact Us
- News & Events
Biopta
Biopta is a spinout of an established and growing pharmaceutical contract research organisation (CRO) from Glasgow Caledonian University, which provides drug-tissue interaction measurement services to the pharmaceutical, biotechnology, academic and research industries. Biopta is also developing novel testing instruments for the same customer base.
Biopta co-founders Drs Chris Hillier and David Bunton of Caledonian developed and patented the new instrument technology. It combines advances in both biology and optoelectronics.
Biopta's proprietary system, Perf-Exion®, addresses a critical bottleneck in pre-clinical testing of drug leads, delivering significant improvements in the throughput, sensitivity and cost of tissue testing. Perf-Exion is a platform technology that can be used for traditional lead discovery testing, toxicology screening and in emerging markets, for example, gene therapy testing. Perf-Exion addresses a $2 billion market.
Awards
- Unisys John Logie Baird Award for Innovation
- Scottish Enterprise Proof of Concept Fund Award
- Royal Society/Scottish Enterprise Biotechnology Enterprise Fellowship
- Scottish Executive SMART Award
Key Staff
- Prof Chris Hillier (CEO)
- Dr Dave Bunton (COO)
- Ms Nicola Barnstaple (Business Development Manager)